{"id":222,"date":"2021-11-21T13:40:30","date_gmt":"2021-11-21T13:40:30","guid":{"rendered":"http:\/\/eurosoi.org\/?p=222"},"modified":"2021-11-21T13:40:30","modified_gmt":"2021-11-21T13:40:30","slug":"%ef%bb%bfgriffith-j-black-j-faerman-c-swenson-l-wynn-m-lu-f-lippke-j-saxena-k","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=222","title":{"rendered":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K"},"content":{"rendered":"<p>\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. and FLT3-ITD to a similar degree in HEK293 and Ba\/F3 cells, and similarly suppressed FLT3 downstream signaling molecules (including ERK1\/2 and STAT5) in <a href=\"https:\/\/www.adooq.com\/alantolactone.html\">Alantolactone<\/a> both the presence and absence of FL in MOLM-13 cells. Co-crystal structure analysis showed that gilteritinib bound to the ATP-binding pocket of FLT3. These results suggest that gilteritinib has therapeutic potential in FLT3-mutated AML patients with FL overexpression. induce constitutive kinase activation that is independent of FL, and occurs in approximately one-third of acute myeloid leukemia (AML) patients [4, 5]. In particular, in-frame duplications of 3 to 400 base pairs in the JMD, known as internal tandem duplications (ITDs), are the most common mutations, occurring in up to 30% of patients with AML, and are associated with poor prognosis [4C7]. Activating point mutations in the TKD are also observed in patients with Alantolactone AML, but at a lower frequency than ITD mutations [5, 8]. These activating mutations are oncogenic and render a state of oncogene addiction in this disease [5, 9C11]. Therefore, FLT3 is considered a promising drug target in AML patients with mutations. A number of FLT3 inhibitors, including gilteritinib, midostaurin, quizartinib, and sorafenib, have been evaluated in clinical trials [12C15]. In 2017, the US Food Alantolactone and Drug Administration (FDA) and European Medicines Agency approved midostaurin for the treatment of adult patients with newly diagnosed AML with mutation in combination with standard chemotherapy [16]. Gilteritinib is a selective FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD mutations, and is classified as an ATP-competitive type I inhibitor [17]. Based on a phase 3 clinical trial, gilteritinib was recently approved by the Pharmaceuticals and Medical Devices Agency and FDA as monotherapy for patients with relapsed\/refractory resistance mutations [19], other gene mutations such as [20], and altered protein expression such as that of FL [21], AXL kinase [22, 23], Pim kinase [24], or FGF2 [25]. In particular, one study reported that increased plasma concentrations of FL after chemotherapy induces resistance to FLT3 inhibitorsincluding midostaurin, quizartinib, sorafenib, and lestaurtinibin AML cells with (mutations co-express = 5). Tumor volume was measured on day 18, and data are shown as mean SEM (= 6). (C) Mice engrafted with FL-expressing or mock MOLM-13 cells were orally administered gilteritinib or quizartinib <a href=\"http:\/\/www.earthmagazine.org\/earth\/article\/25a-7d9-9-2\"> MAPKK1<\/a> at 30 mg\/kg or 3 mg\/kg, respectively. Tumor volume was measured, and data are shown as mean SEM (= 10). Tumor volume on day 11 was compared between the gilteritinib-treated group and quizartinib-treated group using Students 0.01. Abbreviations: FL, FLT3 ligand; ND, not recognized; N. S., not significantly different. Next, we evaluated the antitumor activities of gilteritinib and quizartinib in these xenograft mouse models. Once-daily administration of gilteritinib at 30 mg\/kg or quizartinib at 3 Alantolactone mg\/kg per day for 11 days inhibited the growth of mock MOLM-13 tumors by 97% or 96%, respectively, indicating that the antitumor efficacies of gilteritinib (30 mg\/kg) and quizartinib Alantolactone (3 mg\/kg) in the mock-cell xenograft model were comparable (Number 2C). When quizartinib (3 mg\/kg) was given to mice with FL-expressing MOLM-13 tumors, tumor growth was inhibited by 66%, indicating that the presence of FL attenuated the antitumor activity of quizartinib compared with that of gilteritinib (Number 2C). As expected from our results, gilteritinib (30 mg\/kg) showed similar effectiveness to that for mock MOLM-13 tumors, inhibiting FL-expressing MOLM-13 tumor growth by 95% (Number 2C). These results indicate that, unlike quizartinib, FL experienced no effect on the antitumor effectiveness of gilteritinib mutations. One of the critical issues of treatment with FLT3 inhibitors in or experiments, respectively. Quizartinib, midostaurin, and trametinib were dissolved in DMSO for experiments. Quizartinib dihydrochloride was dissolved in 22% 2-hydroxypropyl&#8211;cyclodextrin (HP&#8211;CD) for experiments. Recombinant human being FLT3 ligand protein was purchased.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. and FLT3-ITD to a similar degree in HEK293 and Ba\/F3 cells, and similarly suppressed FLT3 downstream signaling molecules (including ERK1\/2 and STAT5) in Alantolactone both the presence and absence of FL in MOLM-13 cells. <a href=\"https:\/\/eurosoi.org\/?p=222\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-222","post","type-post","status-publish","format-standard","hentry","category-mch-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=222\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. and FLT3-ITD to a similar degree in HEK293 and Ba\/F3 cells, and similarly suppressed FLT3 downstream signaling molecules (including ERK1\/2 and STAT5) in Alantolactone both the presence and absence of FL in MOLM-13 cells. Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=222\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-21T13:40:30+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K\",\"datePublished\":\"2021-11-21T13:40:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222\"},\"wordCount\":613,\"articleSection\":[\"MCH Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=222\",\"name\":\"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2021-11-21T13:40:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=222\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=222#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=222","og_locale":"en_US","og_type":"article","og_title":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. and FLT3-ITD to a similar degree in HEK293 and Ba\/F3 cells, and similarly suppressed FLT3 downstream signaling molecules (including ERK1\/2 and STAT5) in Alantolactone both the presence and absence of FL in MOLM-13 cells. Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=222","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2021-11-21T13:40:30+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=222#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=222"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K","datePublished":"2021-11-21T13:40:30+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=222"},"wordCount":613,"articleSection":["MCH Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=222","url":"https:\/\/eurosoi.org\/?p=222","name":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2021-11-21T13:40:30+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=222#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=222"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=222#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffGriffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=222"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/222\/revisions"}],"predecessor-version":[{"id":223,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/222\/revisions\/223"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}